Catalyst Wire Dossier Catalyst Wire Dossier

Intismeran

V940 · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Intismeran, covering 2026-04-07 to 2026-04-07. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) [Phase 3]

See pricing